Back to top
more

Alcobra Ltd. (ADHD)

(Delayed Data from NSDQ)

$1.46 USD

1.46
1,107,443

+0.06 (4.29%)

Updated Nov 15, 2017 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Arcturus Therapeutics Holdings Inc. [ADHD]

Reports for Purchase

Showing records 1 - 20 ( 68 total )

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Drugs

Record: 1

09/29/2017

Company Report

Pages: 9

To Merge with Arcturus Therapeutics, Creating RNA-Based Biotech Firm

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 25.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Drugs

Record: 2

09/29/2017

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Drugs

Record: 3

08/14/2017

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Drugs

Record: 4

08/11/2017

Company Report

Pages: 6

Strategic Review and Expense Reduction Continues

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 25.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Drugs

Record: 5

05/31/2017

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Drugs

Record: 6

05/31/2017

Company Report

Pages: 8

Q1 Reported In Line, As 40% Reduction in Fixed Costs Is Underway

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 25.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Drugs

Record: 7

03/29/2017

Company Report

Pages: 10

Analyst Day- Addressing the Parents of/and 16-29yo?s Misusing ADHD Meds

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 25.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Drugs

Record: 8

03/29/2017

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Drugs

Record: 9

03/20/2017

Daily Note

Pages: 6

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Drugs

Record: 10

03/19/2017

Company Report

Pages: 7

2017 Conference Takeaways

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 25.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Drugs

Record: 11

02/17/2017

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Drugs

Record: 12

02/16/2017

Company Report

Pages: 9

4Q Earnings In-line, Well-funded; Mgt Comments Reduce Development Risk

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 25.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Drugs

Record: 13

02/09/2017

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Drugs

Record: 14

02/08/2017

Company Report

Pages: 8

Alcobra Intros ADAIR (Abuse- Deterrent, Amphetamine Immediate Release)

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 25.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Drugs

Record: 15

01/18/2017

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Drugs

Record: 16

01/17/2017

Company Report

Pages: 7

Partially Enrolled MEASURE Study Fails to Meet Primary Endpoint

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 25.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Drugs

Record: 17

11/16/2016

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Drugs

Record: 18

11/16/2016

Company Report

Pages: 7

Q3 In Line; Mgt. Preparing for December FDA Meeting

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 25.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Drugs

Record: 19

09/30/2016

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Arcturus Therapeutics Holdings Inc.

Industry: Medical - Drugs

Record: 20

09/29/2016

Company Report

Pages: 8

FDA Places Clinical Hold On MDX''s Development; PT Lowered To $7.50

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 25.00

Research Provided by a Third Party
// eof